Introduction
Endothelin 1 (ET 1)' is a recently identified 21-amino acid peptide produced by vascular endothelium in culture and in vivo (1) . ETl is the most potent known vasoconstrictor, and it has mitogenic activity in a number of mesenchymal cell types (2) (3) (4) (5) . The effects of ET I on target cells appear to be mediated by activation ofthe dihydropyridine-sensitive calcium channel and phospholipase C, Na+/H+ exchange, and increased intracellular calcium (3) (4) (5) (6) . Two homologous genes that predict similar 2 1-amino acid vasoconstrictive peptides, endothelin 2 (ET2) and endothelin 3 (ET3), have been described (7) . Although there is no evidence that the ET2 locus is transcribed, a cDNA clone encoding the ET3 preprohormone transcript has been characterized (8) . It is thus likely that a family ofhomologous endothelin peptides exists, perhaps allowing intricate regulation of vascular tone.
Little is known about tissue-and cell type-specific endothelin gene expression. Inoue et al. (7) observed ETI gene transcription in endothelial cells, but were unable to detect transcription of the ET1, ET2, or ET3 gene in a variety of human tissues including the brain. In experiments with 3'-untranslated ETl and ET3 cDNA fragments that do not crosshybridize, our laboratory has detected expression of these genes in human heart, kidney, lung, spleen, and pancreas (8) , although we have not identified the cell types responsible for transcription. Endothelin binding sites have been demonstrated in a number of rat tissues including heart, lung, intestine, adrenal gland, and arterial smooth muscle (9) . In addition, endothelin binding sites have been demonstrated in brain tissue, and ET1 has been shown not to cross the blood-brain barrier (9) . This would imply that one of the endothelins or a related peptide is synthesized in cells within the brain. A number of other peptides with cardiovascular functions, such as atrial natriuretic peptide and angiotensin, are expressed in both the brain and peripheral tissue (10, 1 1). Finally, endothelium-dependent relaxing factor has recently been shown to function as a neuromodulator by serving as an intercellular messenger in the brain (12) .
In this study we demonstrate the presence of mRNA in cells of the nervous system that hybridize to an ET I cDNA. In addition, we show that neurons synthesize a protein recognized by an antibody directed against ET1.
Methods
Source ofhuman brain tissue. The brain tissue used in these studies was obtained from nine individuals treated regularly at the Massachusetts General Hospital (Boston, MA) who died ofsystemic diseases and had no clinical evidence of neurological disease. There were no neuropathological findings in these patients at autopsy. Some of the RNA samples used in the RNA blots were made from the tissue of a 16-yr-old patient with cystic fibrosis. He died from a respiratory arrest, and at autopsy had embolic infarcts in multiple organs including the brain. There was no underlying neurological illness in this patient, and all brain tissue used in the preparation of RNA had normal histology except area 17, which had evidence of acute infarction.
Post-mortem human brain tissue from the frontal, temporal, parietal, and occipital cortex with underlying white matter, the striatum, hypothalamus, hippocampus, amygdala, and cerebellum were obtained within 8 h ofdeath, snap-frozen in 2-methyl butane cooled with dry ice, and stored at -80'C until use. A portion of the tissue was assayed by RNA blot hybridization. The remainder was used for in situ hybridization and immunocytochemical studies. Tissue blocks immediately adjacent to those frozen were embedded in paraffin, sectioned (8 gm thick), dewaxed, rehydrated, and used for immunohistochemistry.
RNA blot hybridization. Cellular RNA from various regions of the adult brain was prepared by guanidinium isothiocyanate extraction and centrifugation through cesium chloride (13) . RNA was resus-pended in TE (10 mM Tris, 1 mM EDTA, pH 7.6) and quantitated by determining optical density at 260 nm. 10 ,g of each RNA was fractionated on a 1.3% formaldehyde-agarose gel and equal loading of the samples was verified by ethidium bromide staining ofthe gel. RNA was transferred to Nitroplus 2000 nylon membranes (Micron Separations Inc., Westboro, MA) and hybridization was performed with a 32P-labeled, random-primed, 1.2-kb Eco RI fragment of an ETI cDNA or a 1.9-kb Sac I fragment of a von Willebrand factor cDNA for 16 h at 370C according to standard techniques (14, 15) . In addition, a 1.3-kb Pst I-Eco RI restriction fragment containing the 3'-untranslated portion of an ET3 cDNA was used to probe the blots (8) . After each hybridization the blot was washed in 150 mM sodium chloride, 15 mM sodium citrate, and 0.1% SDS at 550C and exposed to Kodak XAR film for 72 h at -70'C.
In situ hybridization. A 701-bp Eco RI-Hind III ETI cDNA restriction fragment was cloned into the pGEM3 vector, and sense and antisense cRNA transcripts were synthesized with T7 and SP6 polymerases (Promega Corp., Madison, WI) in the presence of 35[S]UTP to a specific activity of 108-109 dpm/,g. Sections were fixed in 4% paraformaldehyde and treated with 0.3% Triton X-100 followed by 1 ;g/ml ofproteinase K (16, 17) . After acetylation the sections were hybridized for 16 h at 500C with -106 dpm of "[S]UTP-labeled antisense (or sense) cRNA probe per cm2 of tissue. The slides were washed for 15 min (four times) in a solution of 1X SSC (300 mM sodium chloride and 30 mM sodium citrate), 10 mM DTT, 50% formamide, and 0.5% Triton X-100 at 50°C. cRNA probe was digested with 50 Mg/ml RNAse A in 10 mM Tris and 1 mM EDTA containing 10 mM DTT. Sections were further washed in 2X SSC with 1 mM DTT and then 0.2X SSC with I mM DTT (each step for 30 min at 37°C). The sections were dehydrated through graded alcohol solutions containing 0.3 M ammonium acetate. The slides were coated with Kodak NTB2 emulsion and exposed for 1-2 wk.
Immunocytochemistry. Cryostat sections adjacent to those used for in situ hybridization were immunolabeled with a 1:100 dilution of a rabbit polyclonal antibody to ETl (Peninsula Laboratories, Inc., Belmont, CA) using the avidin-biotin-horseradish peroxidase method (Vector Laboratories, Inc., Burlingame, CA) according to the manufacturer's protocol. Paraffin-embedded sections fixed in 10% formaldehyde were treated with 0.1% trypsin for 10 min at 37°C before immunostaining. The sections were examined by both bright-and dark-field microscopy.
Results
RNA blot hybridization was used to identify mRNA transcribed from one or more ofthe endothelin genes (ET mRNA). RNA samples from a variety of human brain and spinal cord regions were analyzed by hybridization with a 1.2-kb Eco RI fragment of a previously characterized ETI cDNA (14) . Hybridization to a 2.1-kb message ( Fig. 1 ) indicated the presence of ET mRNA in most ofthe samples, with the lane containing RNA from the striatum revealing the greatest activity. ET mRNA detected by blot hybridization could reflect endothelin gene expression in endothelial cells of the vasculature of the brain. To evaluate the contribution by endothelial cells to the ET mRNA detected by hybridization in each of the tissue RNA samples, a separate hybridization to an endothelial cellspecific probe (von Willebrand factor) was performed (Fig. 1) . The different pattern of hybridization between these two probes provided evidence that the signal observed with the ET1 probe did not reflect ET mRNA restricted to blood vessels. This data suggested that one or more of the endothelin genes might be expressed in the brain and spinal cord in cells other than endothelial cells. When this same RNA blot was studied with a 3'-untranslated probe specific for ET3 mRNA, no hybridization was observed (8, data not shown). Thus, it is unlikely that the ET mRNA represents expression of this member of the endothelin gene family.
To determine which cells of the central nervous system v~4 { Figure 1 . RNA blot hybridization analysis of Fig. 2 a) ; equivalent amounts of sense RNA probe failed to label endothelial cells (Fig. 2 b) .
Labeling of neuroectodermal cells in the cerebral cortex and subcortical nuclei was observed with the ETl antisense cRNA probe. In general, the intensity of labeling in these cells was low compared with endothelial cells. However, the density of labeled cells and the intensity of labeling were striking in grey matter of the striatum and, to an even greater extent, in the hypothalamus. These labeling characteristics were comparable to those observed for endothelial cells (Fig. 2 c) . Although cells containing ET mRNA could not be absolutely identified, most appeared to be neuronal. The characteristic single-cell pattern of the labeled cells within the neuropil supports this conclusion. Comparison of antisense-probed sections with adjacent sections hybridized with the sense cRNA probe demonstrates specificity of binding to mRNA. The possibility of glial cell labeling cannot be excluded in this type ofstudy, however.
To determine whether the ET mRNA detected by RNA blot and in situ hybridization was associated with protein synthesis, we performed immunohistochemical studies on cryostat sections adjacent to those used in the in situ hybridization studies, as well as paraffin-embedded sections of hypothalamus from four additional patients. Although the commercially available rabbit polyclonal antibody (Peninsula Laboratories, Inc.) was raised by immunization with the ETl peptide, the antibody is known to cross-react with ET3 and is very likely to cross-react with ET2 (ET2 and ETl share 19 of 21 amino acids). Endothelin immunoreactivity may thus represent expression of one or more endothelin peptides.
Intense immunostaining of vascular endothelial cells from medium-and large-diameter parenchymal and arachnoidal blood vessels was evident in all sections (Fig. 3, al and b) , and when the antibody was adsorbed to a 30-fold excess ofpurified ETl peptide before application to the cryostat sections endothelin immunoreactivity was abolished (Fig. 3 a2) . Examination of the sections by bright-field microscopy revealed only low-level immunoreactivity in neuroectodermal cells, which is consistent with observations from the in situ hybridization studies. To increase the visibility of stained structures and to better appreciate the distribution of endothelin immunoreactivity in neuroectodermal cells, we examined the sections by dark-field microscopy. The dark-field examination (Fig. 3 b) revealed a larger number of immunoreactive small blood vessels than could be detected by bright-field examination. Diffuse, low-level endothelin immunoreactivity was evident in neurons scattered throughout the brain. For example, in the CA3 region ofthe hippocampal formation most ofthe pyramidal neurons were stained (iig. 3 c), and endothelin immunoreactivity was evident in cell bodies and neural processes (Fig.  3 d) .
High magnification provided convincing evidence of endothelin immunoreactivity in the cytoplasm of various cell types. Most striking was the immunostaining in the cytoplasm of vascular endothelial cells (Fig. 4 A) . Among neuronal cells, 1* aT Figure 3 . Immunocytochemical demonstration of endothelin immunoreactivity in the human brain. Cryostat sections adjacent to those used for in situ hybridization were immunolabeled with rabbit polyclonal antibody to ETI (Peninsula Laboratories, Inc.) by the avidin-biotin-horseradish peroxidase method. The sections were examined by both bright-and dark-field microscopy. a], Note the intense immunoreactivity in endothelial cells (arrows). a2, All specific binding was abolished when the antibody was preadsorbed to an excess of ETI peptide (arrow indicates unstained endothelial cells in a blood vessel). Dark-field illumination disclosed (b) a larger number of stained blood vessels (arrows), (c) low-level immunoreactivity in many neurons including the pyramidal cells of the hippocampal formation (CA3 region shown), and (d) immunostaining of neuroectodermal cell bodies (open arrows) and neural processes (curved arrow) in the temporal cortex. X260. endothelin immunoreactivity was most apparent in magnocellular neurons ofthe supraoptic and periventricular nuclei in the hypothalamus (Fig. 4, B-E) . However, low levels of endothelin immunoreactivity were detected in neurons of all sizes in most hypothalamic nuclei and elsewhere in the brain.
There appeared to be significant variability in the number of endothelin-containing cells in the hypothalamus between the different specimens of hypothalamic tissue (Fig. 4, B-E) .
Discussion
In this study we demonstrated that endothelin gene expression is not limited to the vascular system. Both RNA blot hybridization analysis and in situ hybridization indicate that ET mRNA is present in cells in various brain regions with diverse functions. Immunocytochemical studies show a widespread distribution of endothelin immunoreactivity and provide convincing evidence that one or more of the endothelin peptides are synthesized in neurons of the central nervous system. Endothelin thus joins the growing list of neuropeptides known to have well-described functions outside of the nervous system. The diffuse distribution of endothelin-producing neurons contrasts sharply with the discrete localization of neurons producing other vascular peptides such as atrial natriuretic factor, vasopressin, and angiotensin 11 (18) . However, the distribution of neurons containing endothelin is similar to that of neurons containing substance P, neurotensin, and cholecystokinin (18) .
The diffuse distribution of endothelin-containing neurons suggests that this peptide may function as a general intercellular messenger, either directly as a neurotransmitter or indirectly as a modulator of neurotransmission by other factors. This function in the brain could be completely unrelated to the peptide's function as a vasoconstrictor. The role we postulate for endothelin is quite similar to one recently ascribed to another vasoregulatory substance, endothelium-dependent relaxing factor. This vascular relaxing factor appears to perform a role in neurotransmission in the cerebellum that is unrelated to its vasodilatory role in the blood vessel wall (12) . (19) . Thus, endothelin may modulate the regulation of blood pressure indirectly through the central nervous system and directly through the peripheral vascular system. It has been suggested that angiotensin II and atrial natriuretic factor regulate blood pressure and blood volume through a similar dual action (10, 1 1). Although the nucleic acid probes and antibodies used in these studies derive from the endothelin first described by Yanagisawa et al. (1), i.e., ET1, the data reported here may reflect expression of other members of an endothelin gene family. Recently Inoue et al. cloned and characterized two genomic fragments containing sequences homologous to DNA encoding the original ET1 (7). These sequences predict the related 21-amino acid peptides ET2 and ET3. ET2 and ET3 differ from ETl by two and six amino acids, respectively. Given the amino acid sequence homology among these peptides and the fact that they cross-hybridize at the genetic level, it is difficult to be certain about which endothelin gene is expressed in the human brain. The commercial polyclonal antibody used in our studies was raised against the complete 21-amino acid ETl peptide; thus the antibody would be expected to cross-react with peptides encoding ET2 or ET3. Because the DNA and RNA probes we used were derived from an ETI cDNA and contained sequences encoding ETI (14) , the cDNA probe could have detected mRNA from the ET2 or ET3 genes on the RNA blot (the hybridization and washing conditions were not stringent). However, the likelihood of ET2 and ET3 transcripts being detected was less in the in situ experiments, in which the washing conditions were stringent.
Thus, although we cannot be certain about which endothelin mRNA we detected, ETI mRNA seems most likely.
Further evidence of ETl expression in the brain comes from cDNA clones isolated from a human hypothalamic library. These clones hybridize to a 3'-untranslated ET I cDNA fragment under stringent conditions and probably represent ETl cDNAs (Bloch, K. D., and T. Quertermous, unpublished observations). It is clear that ET3 is expressed in the hypothalamus as well, since we have cloned and characterized ET3 cDNAs from the same library (8) . However, ET3 expression appears to be limited to the hypothalamic region of the brain because we have been unable to detect ET3 mRNA in other brain regions by RNA blot hybridization.
The effect ofendothelin on calcium channels also points to a neuronal function for this peptide. Endothelin has been shown to activate the dihydropyridine-sensitive, voltage-dependent calcium channel in vascular smooth muscle cells (6 (21) support the hypothesis that endothelin functions as a neuromodulator through the L type calcium channel. They reported that endothelin is able to induce depolarization of the ventral root in the newborn rat spinal cord. Because both nicardipine and a substance P antagonist inhibited the depolarization, the authors postulated that endothelin acted through the dihydropyridine-sensitive calcium channel to stimulate release ofthe neurotransmitter substance P. Thus, it is possible that endothelin may function as a neurotransmitter or neuromodulator by activating the dihydropyridine-sensitive L type channel in neurons ofthe central nervous system.
